Is TARA or FRMM more profitable?

Protara Therapeutics' return on equity of -38.70% beat Forum Markets' return on equity. Company Net Margins Return on Equity Return on Assets Protara Therapeutics N/A -38.70% -36.02% Forum Markets N/A -242.09% -135.46%

Does the media prefer FRMM or AKBA?

In the previous week, Forum Markets and Forum Markets both had 2 articles in the media. Forum Markets' average media sentiment score of 1.87 beat Akebia Therapeutics' score of 0.94 indicating that Forum Markets is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Forum Markets 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Akebia Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is PRLD or FRMM more profitable?

Prelude Therapeutics' return on equity of -118.24% beat Forum Markets' return on equity. Company Net Margins Return on Equity Return on Assets Prelude Therapeutics N/A -118.24% -66.12% Forum Markets N/A -242.09% -135.46%

Does the media favor PRLD or FRMM?

In the previous week, Prelude Therapeutics and Prelude Therapeutics both had 2 articles in the media. Forum Markets' average media sentiment score of 1.87 beat Prelude Therapeutics' score of 0.94 indicating that Forum Markets is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prelude Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Forum Markets 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor EDIT or FRMM?

In the previous week, Editas Medicine had 34 more articles in the media than Forum Markets. MarketBeat recorded 36 mentions for Editas Medicine and 2 mentions for Forum Markets. Forum Markets' average media sentiment score of 1.87 beat Editas Medicine's score of 0.75 indicating that Forum Markets is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Editas Medicine 7 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Forum Markets 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has preferable earnings & valuation, FRMM or MGNX?

MacroGenics has higher revenue and earnings than Forum Markets. MacroGenics is trading at a lower price-to-earnings ratio than Forum Markets, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Forum Markets $6.55M 9.82 -$450.52M -$36.07 N/A MacroGenics $149.50M 1.81 -$74.62M -$1.10 N/A

Is FRMM or MGNX more profitable?

Forum Markets has a net margin of 0.00% compared to MacroGenics' net margin of -44.79%. MacroGenics' return on equity of -147.80% beat Forum Markets' return on equity. Company Net Margins Return on Equity Return on Assets Forum Markets N/A -242.09% -135.46% MacroGenics -44.79% -147.80% -28.40%

Does the media prefer FRMM or MGNX?

In the previous week, MacroGenics had 1 more articles in the media than Forum Markets. MarketBeat recorded 3 mentions for MacroGenics and 2 mentions for Forum Markets. Forum Markets' average media sentiment score of 1.87 beat MacroGenics' score of 0.44 indicating that Forum Markets is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Forum Markets 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive MacroGenics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Forum Markets (FRMM) Competitors

$4.42 +0.16 (+3.63%)

As of 02:12 PM Eastern

Compare

FRMM vs. TARA, AKBA, PRLD, EDIT, and MGNX

Should you buy Forum Markets stock or one of its competitors? MarketBeat compares Forum Markets with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Forum Markets include Protara Therapeutics (TARA), Akebia Therapeutics (AKBA), Prelude Therapeutics (PRLD), Editas Medicine (EDIT), and MacroGenics (MGNX). These companies are all part of the "pharmaceutical products" industry.

How does Forum Markets compare to Protara Therapeutics?

Protara Therapeutics (NASDAQ:TARA) and Forum Markets (NASDAQ:FRMM) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and institutional ownership.

Protara Therapeutics' return on equity of -38.70% beat Forum Markets' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protara Therapeutics	N/A	-38.70%	-36.02%
Forum Markets	N/A	-242.09%	-135.46%

Protara Therapeutics has higher earnings, but lower revenue than Forum Markets. Protara Therapeutics is trading at a lower price-to-earnings ratio than Forum Markets, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protara Therapeutics	N/A	N/A	-$57.44M	-$1.34	N/A
Forum Markets	$6.55M	9.82	-$450.52M	-$36.07	N/A

38.1% of Protara Therapeutics shares are owned by institutional investors. Comparatively, 4.1% of Forum Markets shares are owned by institutional investors. 7.6% of Protara Therapeutics shares are owned by insiders. Comparatively, 15.1% of Forum Markets shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Protara Therapeutics presently has a consensus target price of $26.25, suggesting a potential upside of 459.70%. Forum Markets has a consensus target price of $10.00, suggesting a potential upside of 125.99%. Given Protara Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Protara Therapeutics is more favorable than Forum Markets.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protara Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Forum Markets	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, Protara Therapeutics and Protara Therapeutics both had 2 articles in the media. Forum Markets' average media sentiment score of 1.87 beat Protara Therapeutics' score of 1.44 indicating that Forum Markets is being referred to more favorably in the news media.

Company	Overall Sentiment
Protara Therapeutics	Positive
Forum Markets	Very Positive

Protara Therapeutics has a beta of 1.53, meaning that its share price is 53% more volatile than the broader market. Comparatively, Forum Markets has a beta of 1.51, meaning that its share price is 51% more volatile than the broader market.

Summary

Protara Therapeutics beats Forum Markets on 9 of the 14 factors compared between the two stocks.

How does Forum Markets compare to Akebia Therapeutics?

Forum Markets (NASDAQ:FRMM) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

In the previous week, Forum Markets and Forum Markets both had 2 articles in the media. Forum Markets' average media sentiment score of 1.87 beat Akebia Therapeutics' score of 0.94 indicating that Forum Markets is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Forum Markets	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Akebia Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Akebia Therapeutics has higher revenue and earnings than Forum Markets. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Forum Markets, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forum Markets	$6.55M	9.82	-$450.52M	-$36.07	N/A
Akebia Therapeutics	$232.40M	1.19	-$5.34M	-$0.08	N/A

Forum Markets presently has a consensus target price of $10.00, indicating a potential upside of 125.99%. Akebia Therapeutics has a consensus target price of $4.67, indicating a potential upside of 350.89%. Given Akebia Therapeutics' higher possible upside, analysts clearly believe Akebia Therapeutics is more favorable than Forum Markets.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forum Markets	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Akebia Therapeutics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

4.1% of Forum Markets shares are owned by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are owned by institutional investors. 15.1% of Forum Markets shares are owned by company insiders. Comparatively, 4.3% of Akebia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Forum Markets has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -8.83%. Akebia Therapeutics' return on equity of -62.72% beat Forum Markets' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forum Markets	N/A	-242.09%	-135.46%
Akebia Therapeutics	-8.83%	-62.72%	-5.66%

Forum Markets has a beta of 1.51, suggesting that its share price is 51% more volatile than the broader market. Comparatively, Akebia Therapeutics has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market.

Summary

Forum Markets and Akebia Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Forum Markets compare to Prelude Therapeutics?

Prelude Therapeutics (NASDAQ:PRLD) and Forum Markets (NASDAQ:FRMM) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation and dividends.

79.7% of Prelude Therapeutics shares are held by institutional investors. Comparatively, 4.1% of Forum Markets shares are held by institutional investors. 49.2% of Prelude Therapeutics shares are held by insiders. Comparatively, 15.1% of Forum Markets shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Prelude Therapeutics' return on equity of -118.24% beat Forum Markets' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prelude Therapeutics	N/A	-118.24%	-66.12%
Forum Markets	N/A	-242.09%	-135.46%

Prelude Therapeutics currently has a consensus price target of $7.67, indicating a potential upside of 94.88%. Forum Markets has a consensus price target of $10.00, indicating a potential upside of 125.99%. Given Forum Markets' stronger consensus rating and higher probable upside, analysts plainly believe Forum Markets is more favorable than Prelude Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Forum Markets	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, Prelude Therapeutics and Prelude Therapeutics both had 2 articles in the media. Forum Markets' average media sentiment score of 1.87 beat Prelude Therapeutics' score of 0.94 indicating that Forum Markets is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prelude Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Forum Markets	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Prelude Therapeutics has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market. Comparatively, Forum Markets has a beta of 1.51, indicating that its share price is 51% more volatile than the broader market.

Prelude Therapeutics has higher revenue and earnings than Forum Markets. Prelude Therapeutics is trading at a lower price-to-earnings ratio than Forum Markets, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prelude Therapeutics	$12.14M	25.81	-$99.50M	-$1.00	N/A
Forum Markets	$6.55M	9.82	-$450.52M	-$36.07	N/A

Summary

Prelude Therapeutics beats Forum Markets on 9 of the 15 factors compared between the two stocks.

How does Forum Markets compare to Editas Medicine?

Editas Medicine (NASDAQ:EDIT) and Forum Markets (NASDAQ:FRMM) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment and valuation.

In the previous week, Editas Medicine had 34 more articles in the media than Forum Markets. MarketBeat recorded 36 mentions for Editas Medicine and 2 mentions for Forum Markets. Forum Markets' average media sentiment score of 1.87 beat Editas Medicine's score of 0.75 indicating that Forum Markets is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Editas Medicine	7 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Forum Markets	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Editas Medicine has higher revenue and earnings than Forum Markets. Editas Medicine is trading at a lower price-to-earnings ratio than Forum Markets, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Editas Medicine	$40.52M	8.25	-$160.06M	-$1.23	N/A
Forum Markets	$6.55M	9.82	-$450.52M	-$36.07	N/A

Editas Medicine presently has a consensus target price of $5.40, indicating a potential upside of 58.13%. Forum Markets has a consensus target price of $10.00, indicating a potential upside of 125.99%. Given Forum Markets' stronger consensus rating and higher possible upside, analysts clearly believe Forum Markets is more favorable than Editas Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Forum Markets	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

71.9% of Editas Medicine shares are held by institutional investors. Comparatively, 4.1% of Forum Markets shares are held by institutional investors. 3.1% of Editas Medicine shares are held by insiders. Comparatively, 15.1% of Forum Markets shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Editas Medicine has a beta of 2.14, indicating that its stock price is 114% more volatile than the broader market. Comparatively, Forum Markets has a beta of 1.51, indicating that its stock price is 51% more volatile than the broader market.

Forum Markets has a net margin of 0.00% compared to Editas Medicine's net margin of -281.59%. Forum Markets' return on equity of -242.09% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Editas Medicine	-281.59%	-677.39%	-58.25%
Forum Markets	N/A	-242.09%	-135.46%

Summary

Forum Markets beats Editas Medicine on 9 of the 17 factors compared between the two stocks.

How does Forum Markets compare to MacroGenics?

Forum Markets (NASDAQ:FRMM) and MacroGenics (NASDAQ:MGNX) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, media sentiment, institutional ownership, risk, valuation, profitability and dividends.

4.1% of Forum Markets shares are owned by institutional investors. Comparatively, 96.9% of MacroGenics shares are owned by institutional investors. 15.1% of Forum Markets shares are owned by insiders. Comparatively, 13.6% of MacroGenics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Forum Markets presently has a consensus price target of $10.00, indicating a potential upside of 125.99%. MacroGenics has a consensus price target of $5.50, indicating a potential upside of 29.26%. Given Forum Markets' stronger consensus rating and higher possible upside, equities analysts plainly believe Forum Markets is more favorable than MacroGenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forum Markets	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

Forum Markets has a net margin of 0.00% compared to MacroGenics' net margin of -44.79%. MacroGenics' return on equity of -147.80% beat Forum Markets' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forum Markets	N/A	-242.09%	-135.46%
MacroGenics	-44.79%	-147.80%	-28.40%

MacroGenics has higher revenue and earnings than Forum Markets. MacroGenics is trading at a lower price-to-earnings ratio than Forum Markets, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forum Markets	$6.55M	9.82	-$450.52M	-$36.07	N/A
MacroGenics	$149.50M	1.81	-$74.62M	-$1.10	N/A

Forum Markets has a beta of 1.51, meaning that its share price is 51% more volatile than the broader market. Comparatively, MacroGenics has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market.

In the previous week, MacroGenics had 1 more articles in the media than Forum Markets. MarketBeat recorded 3 mentions for MacroGenics and 2 mentions for Forum Markets. Forum Markets' average media sentiment score of 1.87 beat MacroGenics' score of 0.44 indicating that Forum Markets is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Forum Markets	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
MacroGenics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Forum Markets beats MacroGenics on 9 of the 17 factors compared between the two stocks.

Get Forum Markets News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FRMM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FRMM vs. The Competition

Export

Metric	Forum Markets	Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$64.35M	$2.98B	$4.39B	$12.58B
Dividend Yield	N/A	15.22%	6.23%	5.26%
P/E Ratio	-0.12	13.11	21.79	26.31
Price / Sales	9.82	3,282.01	193.87	114.16
Price / Cash	N/A	28.47	56.27	56.90
Price / Book	0.38	6.24	33.32	7.34
Net Income	-$450.52M	-$42.06M	$111.12M	$336.95M
7 Day Performance	-2.53%	1.13%	1.93%	3.65%
1 Month Performance	-14.58%	3.58%	7.87%	7.39%
1 Year Performance	N/A	19.98%	16.47%	37.74%

Forum Markets Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FRMM Forum Markets	3.3179 of 5 stars	$4.43 +3.6%	$10.00 +126.0%	N/A	$64.35M	$6.55M	N/A	7	News Coverage Positive News
TARA Protara Therapeutics	2.9987 of 5 stars	$4.92 -1.0%	$26.25 +433.5%	+50.8%	$279.33M	N/A	N/A	30	Positive News Short Interest Decrease
AKBA Akebia Therapeutics	3.2955 of 5 stars	$1.02 flat	$4.67 +357.5%	-63.5%	$273.62M	$232.40M	N/A	430
PRLD Prelude Therapeutics	4.0777 of 5 stars	$4.27 -1.4%	$7.67 +79.5%	+351.7%	$272.80M	$12.14M	N/A	120	Gap Down
EDIT Editas Medicine	3.4133 of 5 stars	$2.76 +3.4%	$5.40 +95.7%	+83.4%	$270.22M	$38.69M	N/A	230	Trending News Analyst Forecast Options Volume Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FRMM) was last updated on 5/29/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Forum Markets (FRMM) Competitors

FRMM vs. TARA, AKBA, PRLD, EDIT, and MGNX

How does Forum Markets compare to Protara Therapeutics?

Summary

How does Forum Markets compare to Akebia Therapeutics?

Summary

How does Forum Markets compare to Prelude Therapeutics?

Summary

How does Forum Markets compare to Editas Medicine?

Summary

How does Forum Markets compare to MacroGenics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FRMM vs. The Competition

Forum Markets Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Forum Markets (FRMM) Competitors

FRMM vs. TARA, AKBA, PRLD, EDIT, and MGNX

How does Forum Markets compare to Protara Therapeutics?

Is TARA or FRMM more profitable?

Which has stronger earnings & valuation, TARA or FRMM?

Do insiders & institutionals hold more shares of TARA or FRMM?

Do analysts recommend TARA or FRMM?

Does the media favor TARA or FRMM?

Which has more volatility and risk, TARA or FRMM?

Summary

How does Forum Markets compare to Akebia Therapeutics?

Does the media prefer FRMM or AKBA?

Which has stronger valuation and earnings, FRMM or AKBA?

Do analysts prefer FRMM or AKBA?

Do institutionals & insiders believe in FRMM or AKBA?

Is FRMM or AKBA more profitable?

Which has more risk and volatility, FRMM or AKBA?

Summary

How does Forum Markets compare to Prelude Therapeutics?

Do insiders & institutionals believe in PRLD or FRMM?

Is PRLD or FRMM more profitable?

Do analysts rate PRLD or FRMM?

Does the media favor PRLD or FRMM?

Which has more volatility & risk, PRLD or FRMM?

Which has higher earnings and valuation, PRLD or FRMM?

Summary

How does Forum Markets compare to Editas Medicine?

Does the media favor EDIT or FRMM?

Which has preferable valuation and earnings, EDIT or FRMM?

Do analysts rate EDIT or FRMM?

Do insiders and institutionals believe in EDIT or FRMM?

Which has more risk and volatility, EDIT or FRMM?

Is EDIT or FRMM more profitable?

Summary

How does Forum Markets compare to MacroGenics?

Do insiders & institutionals believe in FRMM or MGNX?

Do analysts recommend FRMM or MGNX?

Is FRMM or MGNX more profitable?

Which has preferable earnings & valuation, FRMM or MGNX?

Which has more risk & volatility, FRMM or MGNX?

Does the media prefer FRMM or MGNX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FRMM vs. The Competition

Forum Markets Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools